EU-funded Post-doctoral Fellow in Tumour Immunotherapy and Microenvironment – Field of cander Immunotherapy

KEY SKILLS, EXPERIENCE AND QUALIFICATIONS

– PhD in Cellular and Molecular Biology or Oncology with strong expertise in cancer immunology,
– Strong experience in: Animal experimentation (FELASA authorization, or equivalent, to work with mice is mandatory); Immune phenotyping using CyTOF; RNAseq; Handling large multi-omics data sets; Molecular biology and Cell imaging techniques,
– Independent and self-motivated person, scientific creativity and originality, strong team spirit and collaborative capacity, excellent time management, rigour, perseverance, strong writing skills,
– Fluency in English is mandatory.

BENEFITS

In addition to an attractive salary, the successful candidates will join a highly dynamic research environment and get access to several core facilities and relevant state-of-the-art technologies. She/he will benefit from an outstanding seminar program, international conference attendance and opportunities to collaborate with biotech and pharma companies.

MORE INFORMATION ABOUT “TIME” RESEARCH GROUP

https://www.lih.lu/en/research-scope/research-department/department-of-cancer-research/tumor-immunotherapy-and-microenvironment/

TIME research activities are at the forefront of translating basic knowledge into clinical application. The strategic priority of TIME group relies on generating basic cutting-edge knowledge through discovering and defining druggable gene targets in tumor cells and key pathways in the tumor microenvironment able to reprogram “cold” immune desert tumors, not eligible to immune checkpoint inhibitors, into “hot” inflamed immune infiltrated tumors, which are eligible to immune checkpoint inhibitors. TIME is highly skilled research group recognized to be a driving force in conducting world-class translational research relying on “Bench to Bedside to Clinical Practice” concept through a network collaboration with Pharma and Biotech companies.

Relevant publications:

– Lequeux et al., Oncogene 2021. https://pubmed.ncbi.nlm.nih.gov/34155342/
– Noman et al., Science Advances 2020. https://pubmed.ncbi.nlm.nih.gov/32494661/
– Mgrditchian et al., PNAS 2017 https://pubmed.ncbi.nlm.nih.gov/29078276/
– Baginska et al., PNAS 2013 https://pubmed.ncbi.nlm.nih.gov/24101526/
– Noman, Janji et al., Cancer Res. 2011 https://pubmed.ncbi.nlm.nih.gov/21810913/